PDE4D Recombinant Monoclonal Antibody

說明書

中文名稱：

PDE4D重組抗體
貨號：

CSB-RA996952A0HU
規格：

￥1320
圖片：
Western Blot
Positive WB detected in: THP-1 whole cell lysate
All lanes: PDE4D antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 92, 77, 69, 67, 58, 85, 24, 60, 78, 77, 85, 25 kDa
Observed band size: 92 kDa
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA996952A0HU PDE4D重組單克隆抗體是針對磷酸二酯酶4D亞型開發的高特異性檢測工具，適用于基礎科研領域。該抗體靶向的PDE4D作為cAMP信號通路關鍵調控酶，通過水解環磷酸腺苷參與炎癥反應、神經信號傳導及細胞周期調控等生物學過程。經多種技術平臺驗證，本品在Western Blot實驗中展現出優異的特異性識別能力，推薦工作濃度為1:500-1:5000的寬泛稀釋范圍，可清晰檢測目標蛋白表達水平，且與家族其他亞型無顯著交叉反應。嚴格的質控體系保證不同批次間的高穩定性，配套的驗證數據完整可靠。適用于神經退行性疾病機制研究、免疫細胞信號轉導分析、腫瘤微環境代謝調控等基礎科研方向，特別在探索PDE4D介導的cAMP-PKA通路對神經元可塑性影響、巨噬細胞極化調控等領域具有重要應用價值，為相關信號網絡研究提供優質檢測工具。
Uniprot No.：

Q08499
基因名：

PDE4D
別名：

cAMP-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53) (DPDE3) (PDE43), PDE4D, DPDE3
反應種屬：

Human
免疫原：

A synthesized peptide derived from human PDE4D
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

4D4
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
基因功能參考文獻：
1. PDE4D polymorphism is associated with Gastric and esophageal cancer. PMID: 30202044
2. In Pseudohypoparathyroidism, mutations were found in PRKAR1A, PDE4D, TRPS1, and PTHLH. PMID: 29499646
3. TT genotype of SNP87 in PDE4D was associated with an increased risk for 3-month unfavorable outcome after total ischemic stroke, as well as stroke due to large-artery atherosclerosis and small-artery occlusion, in a Chinese population. PMID: 28225001
4. SNP 83 of PDE4D gene may increase the risk for developing ischemic stroke whereas SNP 87 and SNP45 of PDE4D may not be associated with the risk of ischemic stroke in the North Indian population PMID: 28562233
5. Results provide new information concerning the mechanism whereby the mutations identified in the ACRDYS2 dysregulate PDE4D activity, and give insights into rare diseases involving the cAMP signaling pathway. PMID: 29016851
6. This supports PDE4D5 and RACK1 as potential regulators of cell adhesion, spreading and migration through the non-classical exchange protein activated by cyclic AMP (EPAC1)/Rap1 signalling route PMID: 28069443
7. PDE4D isoform composition is altered in localized prostate cancer and it can be used both as a diagnostic as well as a prognostic biomarker. PMID: 27683107
8. Genetic analysis identified the identical, novel heterozygous missense mutation of the PDE4D gene c.569C>T (p.Ser190Phe) in two patients in same family. This case illustrates the significant phenotypic variability of acrodysostosis even within one family with identical mutations. PMID: 28515031
9. The key residues involved in the interaction with a number of in-house catechol iminoether derivatives, acting as PDE4DIs. PMID: 27546041
10. Screening of PRKAR1A and PDE4D in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism PMID: 26763073
11. p53 induced the transcription of miR-139-5p, which in turn suppressed the protein levels of phosphodiesterase 4D (PDE4D), an oncogenic protein involved in multiple tumor promoting processes. PMID: 27383270
12. High PDE4D expression is associated with melanoma. PMID: 28092671
13. cells on fibronectin suppressed cAMP via enhanced phosphodiesterase (PDE) activity, through direct binding of integrin alpha5 to phosphodiesterase-4D5 PMID: 27595237
14. we performed a meta-analysis of 15 studies, involving 8731 IS patients and 10,756 controls. The results showed nonsignificant association between PDE4D SNP56 and IS risk (T vs. A: OR=1.01, 95%CI=0.88-1.15, P=0.90). Similarly, in the subgroup analysis by ethnicity, no significant association was observed in Asian (T vs. A: OR=1.08, 95%CI=0.80-1.44, P=0.62) or European (T vs. A: OR=0.96, 95%CI=0.86-1.08, P=0.54) population. PMID: 27759001
15. Results support an important association of rs966221 and rs12188950 minor allele and its interaction with increased risk of ischemic stroke risk, and additional interaction between rs966221 and smoking PMID: 28191858
16. RACK1 and beta-arrestin2 inhibit the dimerization of PDE4D5. PMID: 26257302
17. PDE4D acts to allow cAMP-elevating agents to regulate VECADs' role as a sensor of flow-associated fluid shear stress (FSS)-encoded information in arterial endothelial cells. PMID: 26658094
18. PDE4D gene polymorphisms influence the susceptibility for the development of Sudden Sensorineural Hearing Loss in the southern Taiwanese female population. PMID: 26521189
19. focus on recent progress made in PDE4D gene research involving genetic and molecular aspects (review) PMID: 26004910
20. No association was found between single-nucleotide polymorphisms of ALOX5AP or PDE4D and the risk of overall ischemic stroke in a southeastern Chinese population. PMID: 24485247
21. While prior studies have found an association between PDE4D and IL6R polymorphisms and ischemic stroke, the results of this study suggest that this association may be different in a hypertensive population. PMID: 26782593
22. This review show PDE4D mutation is a risk factor for atrial fibrillation and stroke. PMID: 26671126
23. In this article, we review the role of the cAMP signal transduction pathway in memory formation with a particular focus on the recent progress in PDE4D research PMID: 26211680
24. Aberrant DNA methylation of PDE4D promoter alters airway smooth muscle cell phenotypes. PMID: 26181301
25. PDE4D interacts directly with Neuropilins, positive regulators of Hedgehog signal transduction pathway. PMID: 26371509
26. results suggest that the rs918592 and rs2910829 polymorphisms and haplotypes of PDE4D gene are significantly associated with ischemic stroke in Chinese young population. PMID: 23466835
27. The increase in the C allele frequency at 87 single nucleotide polymorphism sites in PDE4D may increase ischemic stroke risk. PMID: 26345966
28. Data highlight an increase in PDE4D7 expression during initial tumorigenesis and further support the findings that PDE4D7 levels fall profoundly in castration resistant prostate cancer, suggesting it as a potential biomarker and therapeutic target. PMID: 26575822
29. Critical residues stabilising PDE4D5 dimerization were defined within the regulatory UCR1 region found in long, but not short, PDE4 isoforms, namely the Arg(173), Asn(174) and Asn(175) (DD1) cluster. PMID: 25546709
30. These studies suggest the pharmacologic inhibition of PDE4D using small-molecule inhibitors is an effective option for prostate cancer therapy. PMID: 25149359
31. This result supports that PDE4D polymorphisms might be involved in the susceptibility to COPD especially in non-emphysematous individuals and that they could also affect the responsiveness of the PDE4 inhibitor treatment. PMID: 24926854
32. structural analysis of the autoinhibited conformation of PDE4 PMID: 25775568
33. The knockdown of PDE4D gene expression inhibited proliferation of STK11-mutated lung cancer lines. Furthermore, challenge with a panel of PDE4-specific inhibitors was shown to selectively reduce the growth of STK11-mutated lung cancer lines. PMID: 25122068
34. specific inhibitory PDE4D mutations can lead to the molecular pathology of acrodysostosis without hormone resistance but that the pathological phenotype may well be dependent on an over-compensatory induction of other PDE4 isoforms PMID: 25064455
35. PDE3A1 and PDE4D3 are integrated into complexes that contain the 5-HT4(b) receptor and may thereby regulate 5-HT4(b) receptor-mediated signaling. PMID: 25101859
36. PKA phosphorylation of the PDE4D7 N-terminus appears to occur constitutively and inhibits PDE4 activity to allow cAMP signalling under basal conditions. PMID: 25680530
37. This study found an association between SNP83 and ischemic stroke in the overall population and in the Asian and Chinese populations, but not among Caucasians. PMID: 24365247
38. haploinsufficiency of PDE4D results in a novel intellectual disability syndrome, the 5q12.1-haploinsufficiency syndrome, with several opposing features compared with acrodysostosis that is caused by dominant negative mutations. PMID: 24203977
39. Patients with the C/C genotype of SNP 83 exhibited significantly more cognitive dysfunction at 1 day (29.7%) than the C/T (15.8%, P = .008) and T/T (12.7%, P = .01) genotypes. PMID: 23863764
40. Multiple factors contribute to the pathogenesis of nasal polyps including genetic predisposition. The PDE4D family has gained interest in the complex pathogenesis of nasal polyposis. This is likely linked to the mucosal inflammatory response. PMID: 24142618
41. results suggest that SNP 83 in PDE4D gene is significantly associated with susceptibility to ischemic stroke in Chinese population PMID: 23799094
42. PDE4D gene variants 83 and 87 did not show any significant association with coronaary heart disease, but may indirectly associate with risk agents of CHD> PMID: 23852788
43. research analyzed association of rs702553 with baseline mean arterial blood pressure in a subset of the African American Study of Kidney Disease and Hypertension Cohort; compared with participants with AA/AT genotypes, those with a TT genotype at rs702553 had significantly lower baseline MAP among study participants on a diuretic PMID: 23778321
44. Comparative analysis of the binding responses of mutations to mAKAP could provide important information about how these mutations modulate PKA and PDE4D3 signaling. PMID: 23806656
45. PDE4D5-beta-arrestin2 complex allowed the recruitment of Epac1 to beta2AR and induced a switch from beta2AR non-hypertrophic signaling to a beta1AR-like pro-hypertrophic signaling cascade. PMID: 23266473
46. although targeted by genomic homozygous microdeletions, PDE4D functions as a tumor-promoting factor and represents a unique targetable enzyme of cancer cells PMID: 23536305
47. An increased frequency of phosphodiesterase 4D TT genotype is associated with risk of myocardial infarction in men over 60 years old. PMID: 23786009
48. Data indicate that missense mutations were identified in all acrodysostosis patients. PMID: 23033274
49. Single nucleotide polymorphisms in PDE4D is associated with response to antipsychotic agents in schizophrenia. PMID: 23241943
50. Data indicate that single-nucleotide polymorphisms (SNPs) in 5-lipoxygenase activating protein (ALOX5AP), phosphodiesterase 4D (PDE4D), and interleukin-1alpha (IL-1alpha) were associated with an increased risk of atherothrombotic stroke (ATS) in Chinese. PMID: 23076369
顯示更多

收起更多
相關疾病：

Acrodysostosis 2, with or without hormone resistance (ACRDYS2)
亞細胞定位：

Apical cell membrane. Cytoplasm. Membrane. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
蛋白家族：

Cyclic nucleotide phosphodiesterase family, PDE4 subfamily
組織特異性：

Expressed in colonic epithelial cells (at protein level). Widespread; most abundant in skeletal muscle. Isoform 6 is detected in brain. Isoform 8 is detected in brain, placenta, lung and kidney. Isoform 7 is detected in heart and skeletal muscle.
數據庫鏈接：

HGNC: 8783

OMIM: 600129

KEGG: hsa:5144

STRING: 9606.ENSP00000345502

UniGene: Hs.117545

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human